Amplifying tumor recognition and drug susceptibility by multivalent ApDC assembly to combat with tumor cell heterogeneity
- 16 June 2025
- journal article
- Published by Elsevier in Biomaterials
- Vol. 324, 123502
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (8210368)
- National Natural Science Foundation of China (T2188102)
This publication has 38 references indexed in Scilit:
- Recent progress of aptamer‒drug conjugates in cancer therapyActa Pharmaceutica Sinica B, 2023
- Enhancing anti‐PD‐1 Immunotherapy by Nanomicelles Self‐Assembled from Multivalent Aptamer Drug ConjugatesAngewandte Chemie International Edition, 2021
- Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomesCell, 2021
- Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumoursJournal of Controlled Release, 2020
- Antibody–drug conjugates for cancerThe Lancet, 2019
- Molecular targeted therapy: Treating cancer with specificityEuropean Journal of Pharmacology, 2018
- Systematic Analysis of the Expression of the Mitochondrial ATP Synthase (Complex V) Subunits in Clear Cell Renal Cell CarcinomaTranslational Oncology, 2017
- Lung cancer: current therapies and new targeted treatmentsThe Lancet, 2017
- Interfacial interactions between poly[L-lysine]-based branched polypeptides and phospholipid model membranesJournal of Colloid and Interface Science, 2003
- Physicochemical characterization of branched chain polymeric polypeptide carriers based on a poly‐lysine backboneBiopolymers, 2003